Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 4
2004 1
2006 3
2007 1
2011 1
2015 1
2016 1
2017 1
2018 1
2020 3
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.
Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M, James A, Kohlbrenner V, Alves M, Khanna D, Highland KB; SENSCIS-ON trial investigators. Allanore Y, et al. Among authors: kohlbrenner v. Ann Rheum Dis. 2022 Dec;81(12):1722-1729. doi: 10.1136/ard-2022-222564. Epub 2022 Aug 16. Ann Rheum Dis. 2022. PMID: 35973804 Free PMC article.
Once-a-day therapy for sinusitis: a comparison study of cefixime and amoxicillin.
Edelstein DR, Avner SE, Chow JM, Duerksen RL, Johnson J, Ronis M, Rybak LP, Bierman WC, Matthews BL, Kohlbrenner VM. Edelstein DR, et al. Among authors: kohlbrenner vm. Laryngoscope. 1993 Jan;103(1 Pt 1):33-41. doi: 10.1288/00005537-199301000-00008. Laryngoscope. 1993. PMID: 8421417 Review.
Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
Li Q, Wallace L, Patnaik P, Alves M, Gahlemann M, Kohlbrenner V, Raabe C, Wang JR, Garry EM. Li Q, et al. Among authors: kohlbrenner v. Rheumatology (Oxford). 2021 Apr 6;60(4):1915-1925. doi: 10.1093/rheumatology/keaa547. Rheumatology (Oxford). 2021. PMID: 33155024 Free PMC article.
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O; SENSCIS trial investigators. Seibold JR, et al. Among authors: kohlbrenner v. Ann Rheum Dis. 2020 Nov;79(11):1478-1484. doi: 10.1136/annrheumdis-2020-217331. Epub 2020 Aug 5. Ann Rheum Dis. 2020. PMID: 32759258 Free PMC article. Clinical Trial.
Evaluation of cefixime in the treatment of bacterial maxillary sinusitis.
Matthews BL, Kohut RI, Edelstein DR, Rybak LP, Rapp M, McCaffrey TV, Kimmelman CP, Parnes SM, Marinaccio AT, Kohlbrenner VM. Matthews BL, et al. Among authors: kohlbrenner vm. South Med J. 1993 Mar;86(3):329-33. doi: 10.1097/00007611-199303000-00016. South Med J. 1993. PMID: 8451674 Clinical Trial.
18 results